Retirement Guys Formula LLC Has $1.85 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Retirement Guys Formula LLC lifted its position in shares of Cencora, Inc. (NYSE:COR) by 7.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,663 shares of the company’s stock after purchasing an additional 471 shares during the quarter. Cencora accounts for 0.9% of Retirement Guys Formula LLC’s portfolio, making the stock its 26th largest position. Retirement Guys Formula LLC’s holdings in Cencora were worth $1,853,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Net Worth Advisory Group lifted its position in Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock valued at $736,000 after acquiring an additional 36 shares in the last quarter. Whittier Trust Co. lifted its holdings in shares of Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock valued at $1,765,000 after purchasing an additional 44 shares in the last quarter. Cullen Frost Bankers Inc. raised its position in Cencora by 1.1% in the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock valued at $1,003,000 after buying an additional 47 shares during the last quarter. Permanent Capital Management LP increased its stake in Cencora by 4.0% in the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company’s stock valued at $344,000 after buying an additional 48 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in Cencora by 4.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock worth $307,000 after buying an additional 48 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on COR shares. Wells Fargo & Company raised Cencora from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Citigroup upped their price objective on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Robert W. Baird boosted their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Finally, Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $306.91.

Cencora Price Performance

Shares of COR opened at $293.08 on Tuesday. The company’s 50-day moving average is $289.16 and its 200-day moving average is $263.77. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The firm has a market capitalization of $56.80 billion, a PE ratio of 34.00, a PEG ratio of 1.45 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the business posted $3.80 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora’s dividend payout ratio is currently 25.52%.

Insider Activity

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now owns 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.